Extended Data Fig. 9: ALOX15 blockade treatment alleviates the type 2 immune response in vitro and in vivo.
From: Single-cell profiling identifies mechanisms of inflammatory heterogeneity in chronic rhinosinusitis
a, Chemokines with insignificant modulation by ALOX15 in IL-4/IL-13-stimulating macrophages co-incubated with or without PD146176 (n = 3 for each group). Unpaired two-sided t-tests. *P < 0.05. b, Representative western blot confirming the knockdown of ALOX15 expression in IL-4/IL-13-stimulating macrophages transfected with ALOX15 siRNA or scramble siRNA (n = 4 for each group). Unpaired two-sided t-tests. **P < 0.01, ****P < 0.0001. c, Chemokines with insignificant modulation by ALOX15 in IL-4/IL-13-stimulating macrophages transfected with ALOX15 siRNA or scramble siRNA (n = 5 for each group). Unpaired two-sided t-tests. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. d, Schematic drawing showing treatment strategy of a papain-induced eosinophilic rhinosinusitis murine model. e, Flow cytometry gating strategy for total immune cells (CD45+), epithelial cells (CD45−EpCAM+), CD4+ T cells (CD45+CD3+CD4+), eosinophils (CD45+Siglec-F+), B cells (CD45+B220+), macrophages (CD45+F4/80+) in murine sinonasal mucosa. f, Representative plots of flow cytometry showing CD45, EPCAM, CD3, CD4, Siglec-F, B220, F4/80 expression in murine sinonasal mucosa under the indicated conditions at Day 16 (n = 4 for each group), related to Fig. 6g. This figure supports Fig. 6.
